Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +58.54% and +50.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?